Speed of onset of response · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ treatment emergent · adults with seasonal affective disorder
Fluoxetine showed no clear difference in adverse events (at least 1 treatment‐emergent adverse event) compared with light therapy (low certainty).
1 finding from 1 review
Response (> 50% improvement on 24‐item HAM‐D SIGH‐SAD) · adults with seasonal affective disorder
Fluoxetine showed no clear difference in response (> 50% improvement on 24‐item HAM‐D SIGH‐SAD) compared with light therapy (low certainty).
1 finding from 1 review
Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SF‐20 & Q‐LES‐Q) Eight weeks · adults with seasonal affective disorder
1 finding from 1 review
Efficacy: response (categorical) YMRS change ≥ 50% from baseline to end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (continuous) MRS mean change from baseline to end of study · acute mania
1 finding from 1 review
Remission · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Acceptability: total withdrawals · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Adverse events · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Response (≥ 50% improvement in BDI‐II score) · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in response (≥ 50% improvement in BDI‐II score) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in remission (BDI‐II total score ≤ 9) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Quality of life (EQ‐5D‐5L) ‐ 12 weeks · treatment‐resistant depression in adults
1 finding from 1 review
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Dropouts ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher dropouts ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher response (≥ 50% reduction in MADRS/HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… showed no clear difference in remission (clinician‐rated) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found